Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Moderna Inc (MRNA)

Moderna Inc (MRNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,038,241
  • Shares Outstanding, K 333,250
  • Annual Sales, $ 135,070 K
  • Annual Income, $ -384,730 K
  • 60-Month Beta N/A
  • Price/Sales 86.08
  • Price/Cash Flow N/A
  • Price/Book 5.66

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.38
  • Number of Estimates 6
  • High Estimate -0.17
  • Low Estimate -0.45
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.68 +19.46%
on 01/07/20
23.20 -8.97%
on 01/22/20
+1.37 (+6.94%)
since 12/24/19
3-Month
15.52 +36.08%
on 11/01/19
23.20 -8.97%
on 01/22/20
+4.53 (+27.31%)
since 10/24/19
52-Week
11.54 +83.02%
on 08/07/19
29.79 -29.10%
on 04/08/19
+6.48 (+44.26%)
since 01/24/19

Most Recent Stories

More News
Coronavirus Spooks Global Markets: Winners and Losers

So far, 18 fatalities and more than 600 are affected by coronavirus in China and the virus is spreading across the boundary, spooking investors.

UAL : 81.90 (-3.51%)
DAL : 58.81 (-2.42%)
AAL : 27.64 (-4.03%)
EL : 205.34 (-1.69%)
RCL : 126.51 (-2.38%)
INO : 4.24 (+10.42%)
MRNA : 21.12 (-1.63%)
CODX : 1.88 (-7.39%)
LVMUY : 91.1900 (-1.17%)
CEPI Grant, Government Aid Drive Coronavirus Focused Biotechs

Several public and private organizations are coming forward to develop vaccines for the new coronavirus by funding developmental programs.

INO : 4.24 (+10.42%)
NVAX : 7.80 (+1.83%)
MRNA : 21.12 (-1.63%)
VIR : 19.95 (+17.49%)
Company News for Jan 23, 2020

Companies in the news are: FSB, AKCA, ALLY, MRNA

FSB : 39.00 (unch)
ALLY : 32.14 (-1.71%)
MRNA : 21.12 (-1.63%)
AKCA : 18.10 (-5.48%)
3 Biotech Stocks Likely to Gain as Coronavirus Spreads

Here we discuss three biotech stocks, which are likely to benefit in case there is an outbreak of coronavirus infection in China.

NVAX : 7.80 (+1.83%)
MRNA : 21.12 (-1.63%)
NNVC : 8.45 (+54.48%)
VIR : 19.95 (+17.49%)
Moderna Announces Funding Award from CEPI to Accelerate Development of Messenger RNA (mRNA) Vaccine Against Novel Coronavirus

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and the...

MRNA : 21.12 (-1.63%)
AZN : 49.28 (-1.83%)
MRK : 85.98 (-2.91%)
Is Moderna (MRNA) Outperforming Other Medical Stocks This Year?

Is (MRNA) Outperforming Other Medical Stocks This Year?

MRNA : 21.12 (-1.63%)
Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area

--mRNA-6981 encodes PD-L1 to treat autoimmune disease, initially to be developed in autoimmune hepatitis

MRNA : 21.12 (-1.63%)
AZN : 49.28 (-1.83%)
MRK : 85.98 (-2.91%)
Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study

--Phase 2 interim data at three months, expected in 2H 2020, intended to inform Phase 3 dose selection

MRNA : 21.12 (-1.63%)
Moderna to Provide Business and Pipeline Updates at the 2020 J.P. Morgan Healthcare Conference

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today...

JPM : 133.15 (-2.48%)
MRNA : 21.12 (-1.63%)
Flagship Unveils Newest Pioneering Platform: Ring Therapeutics

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a...

AXLA : 5.09 (+0.20%)
DNLI : 24.65 (-1.00%)
EVLO : 6.01 (unch)
KLDO : 7.61 (-1.17%)
MRNA : 21.12 (-1.63%)
RUBY : 8.05 (-4.85%)
MCRB : 3.13 (-11.08%)
SYRS : 7.24 (-9.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade MRNA with:

Business Summary

Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company's product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA-...

See More

Key Turning Points

2nd Resistance Point 22.28
1st Resistance Point 21.70
Last Price 21.12
1st Support Level 20.72
2nd Support Level 20.32

See More

52-Week High 29.79
Fibonacci 61.8% 22.82
Last Price 21.12
Fibonacci 50% 20.67
Fibonacci 38.2% 18.51
52-Week Low 11.54

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar